已发表的部分文献: 标题:Evaluation of H3 histone methylation and colony formation in erythroid progenitors treated with thalidomide and sodium butyrate.作者:Fard AD, Kaviani S, Noruzinia M, Soleimani M, Abroun S, Chegeni R, Hajifathali A, Zonoubi Z, Ahmadvand M, Mohammadi MM, Saki N;杂志名称:Lab Hematol 标题:Changing Pattern of Histone H3 Methylation following treatment of erythroid progenitors derived from cord blood CD133+ cells with sodium butyrate and thalidomide作者:Ali Dehghani Fard, Saeid Kaviani, Mehrdad Noruzinia, Masoud Soleimani, Saeid Abroun, Abbas Hajifathali, et al.;杂志名称:Iranian Journal of Blood & Cancer 标题:EZH2 promotes cell proliferation by regulating the expression of RUNX3 in laryngeal carcinoma.作者:Lian R, Ma H, Wu Z, Zhang G, Jiao L, Miao W, Jin Q, Li R, Chen P, Shi H, Yu W;杂志名称:Mol Cell Biochem Epigentek 公司是全球领先的表观遗传学相关研究的技术创新者和产品开发供应商。开发了超过700多个专利产品,为表观遗传学方面的研究和新药研发提供全面系统的解决方案,涵盖样品制备、DNA/RNA甲基化(5-mc, 5-hmc, 5-fc, m6A)/DNMT分析、ChIP、组蛋白甲基化/乙酰化/去乙酰化/磷酸化/SUMO-等领域,提供小分子抑制剂、蛋白质、抗体、以及分析试剂盒产品。